FBR See Sell Off in Aurinia Pharma (AUPH) as Overdone; Remains Positive on Voclosporin

August 17, 2016 6:25 AM EDT
Get Alerts AUPH Hot Sheet
Price: $2.53 +2.02%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade AUPH Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

FBR & Co. affirms Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH) with an Outperform rating and $9 price target following Phase 2b AURA-LV (AURA) data in LN released earlier this week.

The firm commented, While we view the top-line results as positive, the stock pulled back 55%, perhaps on the perception that the deaths observed in the VS arms (12 versus one in the placebo arm) obviates the potential to file accelerated approval. With data coming primarily from subject participation in prior clinical trials in Asia, we had anticipated a Phase III trial would be required to confirm the early positive results and demonstrate that the benefits of VS treatment outweigh the risks prior to voclosporin’s approval. We believe the sell-off is overdone and think the shares offer a significant value proposition.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Add Your Comment